PT - JOURNAL ARTICLE AU - Newman-Tancredi, Adrian AU - Cussac, Didier AU - Quentric, Yann AU - Touzard, Manuelle AU - Verrièle, Laurence AU - Carpentier, Nathalie AU - Millan, Mark J. TI - Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT<sub>1</sub> and 5-HT<sub>2</sub>, Receptor Subtypes AID - 10.1124/jpet.102.039883 DP - 2002 Nov 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - 815--822 VI - 303 IP - 2 4099 - http://jpet.aspetjournals.org/content/303/2/815.short 4100 - http://jpet.aspetjournals.org/content/303/2/815.full SO - J Pharmacol Exp Ther2002 Nov 01; 303 AB - Although certain antiparkinson agents interact with serotonin (5-HT) receptors, little information is available concerning functional actions. Herein, we characterized efficacies of apomorphine, bromocriptine, cabergoline, lisuride, piribedil, pergolide, roxindole, and terguride at human (h)5-HT1A, h5-HT1B, and h5-HT1D receptors [guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) binding], and at h5-HT2A, h5-HT2B, and h5-HT2C receptors (depletion of membrane-bound [3H]phosphatydilinositol). All drugs stimulated h5-HT1A receptors with efficacies (compared with 5-HT, 100%) ranging from modest (apomorphine, 35%) to high (cabergoline, 93%). At h5-HT1B receptors, efficacies varied from mild (terguride, 37%) to marked (cabergoline, 102%) and potencies were modest (pEC50 values of 5.8–7.6): h5-HT1D sites were activated with a similar range of efficacies and greater potency (7.1–8.5). Piribedil and apomorphine were inactive at h5-HT1B and h5-HT1D receptors. At h5-HT2A receptors, terguride, lisuride, bromocriptine, cabergoline, and pergolide displayed potent (7.6–8.8) agonist properties (49–103%), whereas apomorphine and roxindole were antagonists and piribedil was inactive. Only pergolide (113%/8.2) and cabergoline (123%/8.6) displayed pronounced agonist properties at h5-HT2B receptors. At 5-HT2C receptors, lisuride, bromocriptine, pergolide, and cabergoline were efficacious (75–96%) agonists, apomorphine and terguride were antagonists, and piribedil was inactive. MDL100,907 and SB242,084, selective antagonists at 5-HT2A and 5-HT2C receptors, respectively, abolished these actions of pergolide, cabergoline, and bromocriptine. In conclusion, antiparkinson agents display markedly different patterns of agonist and antagonist properties at multiple 5-HT receptor subtypes. Although all show modest (agonist) activity at 5-HT1A sites, their contrasting actions at 5-HT2A and 5-HT2C sites may be of particular significance to their functional profiles in vivo. The American Society for Pharmacology and Experimental Therapeutics